ArticleCommunications chemistry2025
Exploring the macrocyclic chemical space for heuristic drug design with deep learning models.
Article in Communications chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Next-generation Janus kinase inhibitors: Integrating synthetic innovation, structural biology, and computational design for precision drug discovery.Pharmaceutical science advances · 2026Review
- RingKin: portraying the vast macrocyclic chemical universe surrounding kinase drugs.Chemical science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Macrocyclic compounds hold great promise as therapeutic agents. However, their structural optimization remains constrained by the limited availability of bioactive candidates, which in turn hampers the systematic exploration of structure-activity relationships. Here we introduce CycleGPT, a generative chemical language model designed specifically to address these challenges. CycleGPT is characterized by a progressive transfer learning paradigm that incrementally transfers knowledge from pre-trained chemical language models to specialized macrocycle generation, thereby overcoming the data shortage issue. Meanwhile, it adopts an innovative probabilistic sampling strategy that effectively improves the structural novelty of generated macrocycles while ensuring domain-specific adaptability. In a prospective drug design based on CycleGPT and a JAK2 activity prediction model, we successfully developed a new JAK2 drug candidate with a good selectivity profile (inhibiting 17 wild-type kinases) and promising potential for treating polycythemia in vivo, demonstrating the practicality of deep learning methods in macrocyclic drug design.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.